Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 2/12/14  and contains information from public web pages and contributions from the ZoomInfo community.

Jonathan Ratner

Wrong Jonathan Ratner?

Senior Economist

Local Address: Washington D.C., District of Columbia, United States
Westat Inc
1650 Research Blvd.
Rockville, Maryland 20850
United States

Company Description: Westat is an employee-owned research corporation consulting in statistical design, data collection and management, and research analysis work. It is recognized as...   more

Employment History


  • PhD
Web References
06/07/2010 Jonathan Ratner, ..., 16 Nov 2010 [cached]
06/07/2010 Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting
Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting
Jonathan Ratner, Ph.D., gave a presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting in Atlanta, Georgia, on May 18, 2010.
Dr. Ratner is a Westat senior economist specializing in health and labor topics. He took part in an ISPOR Issues Panel, Pragmatic Clinical Trials: How Broad Is Too Broad and How Early Is Too Early? Dr. Ratner's presentation for the panel was titled, Pragmatic Clinical Trials: Health Care Payers' Views of PCT Features and Trade-offs.
Pragmatic clinical trials (PCTs) are a relatively new variant of traditional randomized clinical trials (RCTs). In an RCT-usually funded by a pharmaceutical manufacturer-researchers test a new drug against a placebo. The drug manufacturer makes the RCT's results available to the U.S. Food and Drug Administration (FDA), which approves the new drug for use if convinced that the drug is safe and effective. "However," Dr. Ratner explained, "health care payers-private insurers and public payers such as the Defense Department-typically want to know more than what most RCTs tell them.
Dr. Ratner and a colleague interviewed formulary decisionmakers at private and public payers. These decisionmakers described their views of PCTs and discussed the trade-offs they would make if cost considerations forced trial sponsors to choose between, for example, a broader patient population and an active (non-placebo) comparator. Dr. Ratner's preliminary study results are part of a project for a commercial client.
PROGRAM - Tuesday, May 18, 2010 [cached]
Panelists: Winston Wong PharmD, Associate Vice President, Pharmacy Management, CareFirst BlueCross BlueShield, Baltimore, MD, USA; Don P. Buesching PhD, US Outcomes Research Fellow, Eli Lilly and Company, Indianapolis, IN, USA; Jonathan Ratner PhD, Senior Economist, Westat, Rockville, MD, USA
Category Description, 29 Feb 2008 [cached]
Robert S. Goldfarb and Jonathan Ratner
Jonathan Ratner is a senior economist at Westat, an employee-owned research firm in Rockville, Maryland. Previously, he was an Assistant Director at the Government Accountability Office (GAO), a congressional agency, and an assistant professor at Wellesley College and the State University of New York at Albany. He also served on detail from GAO as a staff member for the U.S. Senate Finance Committee. His academic publications address topics in health economics, macroeconomics, defense economics, and forecasting. He is the author or co-author of numerous GAO reports on health economics and policy. He has testified at congressional hearings and appeared on NBC Nightly News. His email is
- Modern Healthcare - Your Source for Weekly Healthcare Business News, 6 May 2002 [cached]
The focus of the study has not been worked out yet nor has a deadline, but it will likely build on the pilot study and other issues that emerged from the hearing, said Jon Ratner, assistant director of healthcare issues at the GAO and an author of the pilot study.
"We called it a pilot study because we were trying to explore the feasibility of data collection and gain understanding of a pretty complicated marketplace," Ratner said.
The plan of action did not seem to completely assuage the manufacturers, who have been battling GPO business practices for years.
"I'm happy to hear there is a three-month deadline to see some major change.
Westat - News Archives 2010 [cached]
Gad Nathan, Ph.D. (2001)
Jonathan Ratner and Andrew Giffin.
Other People with the name "Ratner":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.